Anebulo Pharmaceuticals Launches Cash Tender Offer for Going Private

Anebulo Pharmaceuticals announced that the board of directors has decided to commence a cash tender offer as part of its plan to "go private" in lieu of the previously announced reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500. Voluntary self tender consists of acquiring up to 300,000 shares at $3.50 price per share While the board of directors believed that the reverse stock split transaction was in the best interest of the company and its stockholders at the time of its proposal, upon review and careful consideration, further discussions with management and its advisors and other relevant factors, the board of directors has determined that the costs of the proposed reverse stock split transaction now outweigh the benefits to the company and its stockholders. The primary cause is the increased number of shares that are now held through accounts with fewer than 2,500 shares, mostly from certain holders who upon announcement of the proposed reverse stock split began acquiring shares through multiple accounts with less than 2,500 shares or splitting their existing holdings, simply in an attempt to receive multiple fractional share payments. This activity resulted in a significant increase in the expected cost of the proposed transaction. Therefore, the board of directors has decided that the increased cost now outweighs the anticipated benefit, and it is in the best interest of the company and its stockholders to abandon the reverse stock split and to commence a voluntary self-tender offer to purchase 300,000 shares at $3.50 in lieu of the reverse split proposal. The tender offer will aid the company in maintaining its number of stockholders at below 300, which is necessary for its "go private" transaction. The board will continue to monitor the cost of a reverse stock split or alternative transaction versus the benefits and may at some point in the future and on such terms as will be decided to be beneficial at that time pursue another transaction if and when deemed to be in the best interest of the company and its stockholders.